Europe Platelet-rich Plasma Market – Insights
Autologous platelet-rich plasma (PRP) is a blood plasma concentrate enriched with platelet count above the baseline of whole blood prepared from patient’s own blood. It is used to accelerate the healing of injured tendons, ligaments, muscles and joints.
Europe platelet-rich plasma market is estimated to account for US$ 75.8 Mn in terms of value by the end of 2027.
Europe Platelet-rich Plasma Market: Drivers
Increasing prevalence of musculoskeletal injuries is expected to boost growth of Europe platelet-rich plasma market over the forecast period. For instance, according to the Study, ‘Prevalence of Musculoskeletal Injuries, Pain, and Illnesses in Elite Female Basketball Players, in Europe, in June 2019, the most frequently injured body parts were lower limbs: more than 60%, representing an injury rate of 0.14 per athletes and a 0.2 pain rate per athlete (during the study period).
Moreover, increasing geriatric population and high adoption of knee osteoarthritis treatment in by the age group is also expected to aid in growth of the market. Aging contributes to soft tissue degeneration and related-disorders, particularly of the knee. For instance, according to the study ‘Osteoarthritis in Europe: Impact on health status, work productivity and use of pharmacotherapies in five European countries’ that examined the impact of peripheral joint osteoarthritis across five European countries, UK (43.6%), France, (25.6%), Germany, (15.2%), Spain, (8.4%), and Italy (7.1%) recorded high prevalence of peripheral joint osteoarthritis, with majority of cases aging 55-74 years.
U.K. held dominant position Europe platelet-rich plasma market in 2019, accounting for 23.5% share in terms of valuee, followed by France.
Figure 1. Europe Platelet-rich Plasma Market Value (US$ Mn), by Country/Region, 2019
Europe Platelet-rich Plasma Market: Restraints
Lack of standardization in preparation and dosage of autologous blood concentrate and platelet-separation techniques is a major factor hindering growth of market. Lack of standardization in preparation and dosage of autologous blood concentrate and platelet-separation techniques lead in uncertainty about the evidence to support the increasing clinical use of platelet-rich plasma therapy as a treatment modality for musculoskeletal injuries, including orthopedic bone and soft-tissue injuries.
Moreover, uncertainty about therapeutic efficacy of platelet-rich plasma is also expected to hamper growth of the market. For instance, the study ‘Current Clinical Recommendations for Use of Platelet-Rich Plasma’ published in Current Reviews in Musculoskeletal Medicine in 2018, found moderate high-quality evidence that supported the use of leukocyte-rich (LR)-PRP injection for patellar tendinopathy and of PRP injection for plantar fasciitis and donor site pain in patellar tendon graft Bone-patellar tendon-bone anterior cruciate ligament reconstruction. Moreover, the review also noted insufficient evidence to routinely recommend PRP for rotator cuff tendinopathy, osteoarthritis of the hip, or high ankle sprains.
Europe Platelet-rich Plasma Market: Opportunities
Increasing adoption of PRP in skeletal muscle injuries is expected to offer lucrative growth opportunities for players in the market. PRP has promotes muscle recovery via anabolic growth factors released from activated platelets. This in turn reduces pain, swelling, and time for recovery in skeletal muscle injuries.
Moreover, technological advancements in PRP such as changes in production protocol (time and RPM/centrifugal force) and output level (volume and concentration above baseline) are also expected to aid in growth of the market.
Kits segment in Europe platelet-rich plasma market was valued at US$ 34.9 Mn in 2019 and is expected to reach US$ 60.4 by 2027 at a CAGR of 7.1% during the forecast period.
Market Trends/Key Takeaways
The demand for pure PRP fibrin therapy has increased significantly in the recent past, especially for the treatment of skin wound ulcers and in oral and maxillofacial surgeries. The platelet-rich fibrin therapy is classified as a second generation platelet concentrate, with rich platelet content and extensive growth factors in the form of fibrin membranes, which are free of any anti-coagulants or other artificial bio-chemical modifications and promote rapid and accelerated wound healing.
Increasing geriatric population in Europe has led to high demand for non-invasive or minimally invasive surgical treatments. PRP therapy is a simple, efficient, and minimally invasive procedure that represents an appropriate biological approach for ensuring tissue regeneration in a very short period of time. Such scenario has led to high adoption of PRP therapy for the treatment of orthopedic related injuries in geriatric patients.
- Directive 2002/98/EC of the European Parliament and Council of January 27, 2003, regulates the approval process for blood and blood-derived products
- This committee is engaged in the establishment of quality, safety, and efficacy of blood products and in setting norms for collection, processing, and distribution of blood components across the European Union countries
- Harmonized regulatory framework for PRP therapies is not present
- Each country has its own approach to PRP regulation within the jurisdiction of national authorities
- Devices must comply with Class II- medical device directive 93/42/EEC.
- Device approval is overseen in each EU country by a governmental body called a ‘Competent Authority.’
- The surgical use of PRP can be considered as an autologous graft within the surgical procedure as regulated by Directive 2004/23/EC
Europe Platelet-rich Plasma Market: Competitive Landscape
Major players operating in Europe include, Arthrex, Inc., Stryker Corporation, Johnson and Johnsons Ltd., Zimmer Biomet Holdings Inc., Terumo Corporation, Glofinn Oy, Medira Ltd., Regen Lab S.A., and Estar Technologies Ltd.
Europe Platelet-rich Plasma Market: Key Developments
In January 2020, SHVI PRP Therapy, announced a new website that is focused specifically at the use of PRP to mitigate hair loss.
In March 2019, CollPlant, a regenerative medicine company, renewed its exclusive distribution agreement with Arthrex for Vergenix STR, an injectable gel comprised of cross-linked bioengineered recombinant human type I collagen, rhCollagen, combined with autologous PRP, for the treatment of tendinopathy.
In January 2019, Generex Biotechnology Corporation entered into a letter of intent to acquire Medisource Partners, an FDA-registered distributor of medical and surgical products including supplies kits to process bone marrow aspirates and PRP biologics at the time of surgery.
In December 2018, Regenexx’s research published in the Journal of Translational Medicine, which involved use of patients' own bone marrow concentrate and PRP products demonstrated positive clinical outcomes for the treatment of osteoarthritis of the knee.